Profile: Pfizer Inc (PFE)
1 Oct 2014
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. Primary Care operating segment includes revenues from human prescription pharmaceutical products primarily prescribed by primary-care physicians. Specialty Care and Oncology operating segment consist of the specialty care business unit and the oncology business unit. In November 2012, the Company acquired NextWave Pharmaceuticals, Inc. On November 30, 2012, the Company completed the sale of its Nutrition business.
Primary Care operating segment includes revenues from human pharmaceutical products primarily prescribed by primary-care physicians, and may include products in the therapeutic and disease areas, such as Alzheimer’s disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, genitourinary, depressive disorder, pain, respiratory and smoking cessation. Examples of products in this segment include Celebrex, Chantix/Champix, Lipitor, Lyrica, Premarin, Pristiq and Viagra. During 2011, sales of Lipitor in the United States were reported in its Primary Care business unit. Specialty Care includes revenues from human pharmaceutical products primarily prescribed by physicians, who are specialists, and may include products in the therapeutic and disease areas, such as anti-infectives, endocrine disorders, hemophilia, inflammation, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. Examples of products in this business unit include BeneFIX, Enbrel, Genotropin, Geodon, the Prevnar/Prevenar franchise, Rebif, ReFacto AF, Revatio, Xalatan, Xyntha and Zyvox. Oncology includes revenues from human prescription pharmaceutical products addressing oncology and oncology-related illnesses. Examples of products in this business unit include Aromasin, Sutent, Torisel and Xalkori.
Established Products and Emerging Markets operating segment comprises the Established Products business unit and the Emerging Markets business unit. Established Products generally includes revenues from human prescription pharmaceutical products that have lost patent protection or marketing in certain countries and/or regions. This business unit also excludes revenues generated in emerging markets. Examples of products in this business unit include Arthrotec, Effexor, Medrol, Norvasc, Protonix, Relpax and Zosyn/Tazocin. Emerging Markets includes revenues from all human prescription pharmaceutical products sold in emerging markets, including Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. Animal Health and Consumer Healthcare operating segment comprises the Animal Health business unit and the Consumer Healthcare business unit. Animal Health includes worldwide revenues from products and services to prevent and treat disease in livestock and companion animals, including vaccines, parasiticides and anti-infectives. Consumer Healthcare includes worldwide revenues from non-prescription products in the therapeutic categories, such as dietary supplements, pain management, respiratory and personal care. Products marketed by Consumer Healthcare include Advil, Caltrate, Centrum, ChapStick, Preparation H and Robitussin.
Revenues from biopharmaceutical products contributed approximately 86% of its total revenues during the year ended December 31, 2011. The Company’s Lipitor product is used for the treatment of elevated LDL-cholesterol levels in the blood. Lyrica is indicated for the management of post-herpetic neuralgia, neuropathic pain associated with diabetic peripheral neuropathy, the management of fibromyalgia, and as adjunctive therapy for adult patients with partial onset seizures in the United States, and for neuropathic pain (peripheral and central), adjunctive treatment of epilepsy and general anxiety disorder in certain countries outside the United States. Prevnar 13/Prevenar 13 is its 13-valent pneumococcal conjugate vaccine for the prevention of various syndromes of pneumococcal disease in infants and young children and in adults 50 years of age and older. Prevnar 13/Prevenar 13 for use in infants and young children has been launched in the United States for the prevention of invasive pneumococcal disease caused by the 13 serotypes in Prevnar 13 and otitis media caused by the seven serotypes in Prevnar, and in the European Union and a number of international markets for the prevention of invasive pneumococcal disease, otitis media and pneumococcal pneumonia caused by the vaccine serotypes. In addition, during the year ended December 31, 2011, Pfizer received approval of Prevnar 13/Prevenar 13 for use in adults 50 years of age and older in the United States for the prevention of pneumococcal pneumonia and invasive pneumococcal disease caused by the 13 serotypes in Prevnar 13, and in the European Union for the prevention of invasive pneumococcal disease caused by the vaccine serotypes. Prevenar 13 for use in adults 50 years of age and older also has been approved in many other international markets.
During 2011, the Company conducted the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) to fulfill requirements in connection with the United States Food and Drug Administration approval of the Prevnar 13 adult indication under its accelerated approval program. CAPiTA is an efficacy trial involving subjects 65 years of age and older that is designed to evaluate whether Prevnar 13 is effective in preventing the first episode of community-acquired pneumonia caused by the serotypes contained in the vaccine. Enbrel is its treatment for moderate-to-severe rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis, a type of arthritis affecting the spine. Under its co-promotion agreement with Amgen Inc. (Amgen), the Company and Amgen co-promote Enbrel in the United States and Canada. Celebrex is for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis worldwide and for the management of acute pain in adults in the United States and certain markets in the European Union. Viagra remains the treatment for erectile dysfunction.
Norvasc is the Company’s product for treating hypertension. Zyvox is used to treat serious Gram-positive pathogens, including methicillin-resistant staphylococcus-aureus. Xalabrands consists of Xalatan, a prostaglandin, which is an agent used to reduce elevated eye pressure in patients with open-angle glaucoma or ocular hypertension, and Xalacom, a fixed combination of prostaglandin (Xalatan) and beta blocker (timolol), available outside the United States. Sutent is for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumors (GIST) after disease progression on, or intolerance to, imatinib mesylate. In May 2011, the United States Food and Drug Administration approved Sutent for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. Geodon/Zeldox is an atypical antipsychotic, is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. Its Premarin family of products address moderate to severe menopausal symptoms. Genotropin, a human growth hormones, is used in children for the treatment of short stature with growth hormone deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short Stature (in the United States only) and Chronic Renal Insufficiency (outside the United States only), as well as in adults with growth hormone deficiency.
Detrol/Detrol LA is a muscarinic receptor antagonist, a prescribed medicine for overactive bladder. Detrol LA is an extended-release formulation taken once a day. Vfend is an agent for treating yeast and molds. Chantix/Champix is an aid to smoking-cessation treatment in adults 18 years of age and older. BeneFIX and ReFacto AF/Xyntha are hemophilia products that assist patients with a lifelong bleeding disorder. BeneFIX is the recombinant factor IX product for the treatment of hemophilia B, while ReFacto AF/Xyntha is recombinant factor VIII products for the treatment of hemophilia A. Both products are indicated for the control and prevention of bleeding in patients with these disorders and in some countries also are indicated for prophylaxis in certain situations, such as surgery. Effexor is an antidepressant for treating adult patients with depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder. Zosyn/Tazocin is the Company’s intravenous antibiotic. Pristiq is approved for the treatment of depressive disorder in the United States and in various other countries. Pristiq has also been approved for treatment of moderate-to-severe vasomotor symptoms associated with menopause in Thailand, Mexico, the Philippines and Ecuador.
Caduet is a single pill therapy combining Lipitor and Norvasc for the prevention of cardiovascular events. Revatio is for the treatment of pulmonary arterial hypertension. Prevnar/Prevenar (7-valent) is its 7-valent pneumococcal conjugate vaccine for preventing invasive, and, in certain international markets, non-invasive pneumococcal disease in infants and young children. Aricept, discovered and developed by Eisai Co., Ltd. (Eisai), is a medicine to treat symptoms of Alzheimer’s disease. The Company co-promotes Aricept with Eisai in the United States and other countries and has a license to sell Aricept in certain other countries. Spiriva is indicated in the United States for the long-term, once-daily, maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema, and for reducing COPD exacerbations. The Company co-promotes Spiriva with Boehringer Ingelheim (BI) in the United States and selected countries on a worldwide basis. Xalkori, the therapy targeting anaplastic lymphoma kinase (ALK) is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is ALK-positive as detected by the United States Food and Drug Administration-approved test, was approved by the United States Food and Drug Administration in August 2011. Inlyta was approved by the United States Food and Drug Administration in January 2012, for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy. On March 10, 2011, the Company initiated a voluntary recall to wholesale and retail customers of all Embeda products.
The Company markets vaccines, anti-infectives, anti-inflammatories, antiemetics and parasiticides. The Company’s products are Startect is a dual-active parasiticide that delivers a spectrum control of parasitic worm infestation in sheep; Improvac/Improvest is a gonadotropin releasing factor (GnRF) product for swine that prevents boar taint; Fostera PCV is a vaccine that protects pigs against porcine circovirus; Palladia is a treatment of mast cell tumors; Convenia is an anti-infective for dogs and cats that delivers a full course of therapy from a single injection; Cerenia is a selective NK-1 receptor antagonist for the treatment and prevention of vomiting in dogs and for the prevention of motion sickness; Revolution/Stronghold is a topically administered parasiticide for dogs and cats that controls a number of different parasites, such as fleas and heartworm; Rimadyl relieves pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery; Draxxin is a single dose anti-infective used to treat infections in cattle and swine; Excede is a single-dose anti-infective used to treat infections in cattle and swine; Zulvac is a vaccine that protects cattle and sheep against bluetongue disease, and Bopriva is a GnRF vaccine, which temporarily reduces undesirable bull behaviors, such as fighting.
The Company’s Consumer Healthcare business unit is the over-the-counter healthcare products business, which sells two of the over-the-counter healthcare brands (Centrum and Advil). Major categories and product lines are Dietary Supplements: Centrum brands (including Centrum, Centrum Silver, Centrum Men’s and Women’s, Centrum Performance, Centrum Specialists, Centrum Cardio, and Centrum Kids), Caltrate, and ProNutrient brands (including Probiotic, Omega-3, and Fruit and Veggie); Pain Management: Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Children’s Advil, Infant’s Advil, and Advil Migraine), and ThermaCare; Respiratory: Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; Personal Care: ChapStick and Preparation H.
235 E 42ND ST
NEW YORK NY 10017
Company Web Links
- UPDATE 1-Esperion drug succeeds in lowering LDL cholesterol -study
- Esperion drug succeeds in lowering LDL cholesterol -study
- Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher
- PRESS DIGEST- New York Times business news - Sept 30
- Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study<4151.T>